Eplontersen May Improve Health Status in Heart Patients
A long-term study shows that the medication could help adults with transthyretin amyloidosis maintain better health.
Updated on Oct. 26, 2026 in Heart Disease
Live Poll
Should medical treatment success be measured by patient quality of life rather than just survival?
A recent post hoc analysis presented at the Heart Failure Society of America meeting shows that eplontersen monotherapy helps preserve health status in patients with transthyretin amyloidosis with cardiomyopathy. These findings, based on 140 weeks of data, offer new insights for older adults managing this condition.
Why it matters
For patients living with transthyretin amyloidosis with cardiomyopathy, maintaining quality of life is a primary treatment goal. This trial analysis helps clarify how monotherapy might impact patient-reported health outcomes compared to placebo over a long-term period.
In a trial of 1,432 participants with a mean age of 76.4 years, eplontersen monotherapy resulted in a 7.6-point higher Kansas City Cardiomyopathy Questionnaire score than placebo after 140 weeks. These findings from the CARDIO-TTRansform trial remain preliminary as post hoc analysis results.
The players
Heart Failure Society of America
A professional organization dedicated to the study and management of heart failure.
The details
The CARDIO-TTRansform trial evaluated the drug by administering 45 mg of eplontersen subcutaneously once monthly to study participants. Researchers measured patient health status using the Kansas City Cardiomyopathy Questionnaire, which assesses physical limitations, symptoms, and quality of life. The data suggests potential benefits for stability and well-being, though results varied when eplontersen was used alongside a TTR stabilizer.
Timeline
140 weeks of patient follow-up were conducted during the trial.
Trial results were presented on October 26, 2026, in Phoenix.
Health Landscape
This analysis adds to the growing body of research from the CARDIO-TTRansform trial regarding therapeutic options for transthyretin amyloidosis with cardiomyopathy. It highlights a shift toward evaluating long-term patient-reported quality of life alongside traditional clinical endpoints.
If you or a loved one are managing transthyretin amyloidosis with cardiomyopathy, these results are worth discussing with your cardiologist to understand how different therapeutic approaches might impact daily function. Always consult your physician before making any changes to your care plan.
The takeaway
Maintaining physical stability and well-being is a central aspect of managing cardiomyopathy. Patients should track symptoms such as exercise tolerance or fatigue and bring these observations to their next cardiology appointment to ensure their treatment plan remains effective.
Further reading
Learn more about the latest research and management strategies on the Heart Disease page.
Source note: This article includes information reported by Healio.
Live Poll
Should medical treatment success be measured by patient quality of life rather than just survival?
